See more : Auri, Inc. (AURI) Income Statement Analysis – Financial Results
Complete financial analysis of Aeterna Zentaris Inc. (AEZS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeterna Zentaris Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pos Malaysia Berhad (4634.KL) Income Statement Analysis – Financial Results
- Steel Authority of India Limited (SAIL.BO) Income Statement Analysis – Financial Results
- PT Pioneerindo Gourmet International Tbk (PTSP.JK) Income Statement Analysis – Financial Results
- Collector AB (publ) (0R8T.L) Income Statement Analysis – Financial Results
- Iceco Inc. (7698.T) Income Statement Analysis – Financial Results
Aeterna Zentaris Inc. (AEZS)
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.58M | 5.64M | 5.26M | 3.65M | 532.00K | 26.88M | 923.00K | 911.00K | 545.00K | 11.00K | 6.18M | 33.67M | 36.05M | 27.70M | 63.24M | 38.48M | 42.07M | 41.39M | 247.39M | 194.03M | 128.33M | 64.28M | 27.50M | 5.61M | 4.25M | 2.79M | 4.47M | 2.04M |
| Cost of Revenue | 398.17K | 157.00K | 90.00K | 2.32M | 410.00K | 2.10M | 0.00 | 0.00 | 249.59K | 0.00 | 51.00K | 26.82M | 27.56M | 18.70M | 16.50M | 19.28M | 12.93M | 11.75M | 156.37M | 111.91M | 75.61M | 49.19M | 18.81M | 749.33K | 705.76K | 1.49M | 1.96M | 1.75M |
| Gross Profit | 4.18M | 5.48M | 5.17M | 1.34M | 122.00K | 24.78M | 923.00K | 911.00K | 295.41K | 11.00K | 6.12M | 6.85M | 8.49M | 9.00M | 46.74M | 19.20M | 29.14M | 29.65M | 91.02M | 82.11M | 52.72M | 15.09M | 8.69M | 4.86M | 3.55M | 1.30M | 2.52M | 291.89K |
| Gross Profit Ratio | 91.31% | 97.22% | 98.29% | 36.56% | 22.93% | 92.17% | 100.00% | 100.00% | 54.20% | 100.00% | 99.17% | 20.33% | 23.56% | 32.50% | 73.91% | 49.90% | 69.26% | 71.62% | 36.79% | 42.32% | 41.08% | 23.48% | 31.58% | 86.63% | 83.40% | 46.51% | 56.25% | 14.29% |
| Research & Development | 13.81M | 12.51M | 6.57M | 1.51M | 1.84M | 2.93M | 10.70M | 16.50M | 17.23M | 23.72M | 21.28M | 20.60M | 24.52M | 19.86M | 44.22M | 57.11M | 37.19M | 27.09M | 26.97M | 25.26M | 34.03M | 15.33M | 14.59M | 10.62M | 8.40M | 6.04M | 4.26M | 3.28M |
| General & Administrative | 8.72M | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M | 8.20M | 7.15M | 11.31M | 9.84M | 8.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -12.11K | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M | 5.10M | 6.75M | 6.89M | 13.69M | 12.32M | 13.25M | 0.00 | 11.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.71M | 8.23M | 7.27M | 5.89M | 7.83M | 12.00M | 13.29M | 13.89M | 18.20M | 13.69M | 12.32M | 13.25M | 16.17M | 11.88M | 16.04M | 17.33M | 20.40M | 17.24M | 42.04M | 35.10M | 22.44M | 11.29M | 4.08M | 1.72M | 1.42M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -13.00K | 8.51M | 90.00K | 146.34K | 1.11M | -1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.81M | 10.84M | 7.15M | 6.30M | 9.43M | 26.61M | 7.47M | 7.26M | 1.54M | 1.16M | 969.37K | 709.21K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.52M | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M | 24.00M | 30.39M | 35.43M | 37.41M | 33.60M | 33.85M | 40.69M | 34.23M | 70.69M | 81.58M | 63.89M | 53.75M | 95.61M | 67.83M | 63.73M | 28.16M | 19.84M | 13.30M | 10.53M | 5.33M | 3.56M | 2.26M |
| Cost & Expenses | 22.92M | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M | 24.00M | 30.39M | 35.43M | 37.41M | 33.65M | 60.67M | 68.25M | 52.93M | 87.20M | 100.86M | 76.82M | 65.50M | 251.98M | 179.75M | 139.34M | 77.35M | 38.65M | 14.05M | 11.24M | 6.82M | 5.52M | 4.01M |
| Interest Income | 1.13M | 4.00K | 7.00K | 4.00K | 593.00K | 278.00K | 75.00K | 150.00K | 143.00K | 168.00K | 185.00K | 6.97M | 6.24M | 207.00K | 349.00K | 0.00 | 0.00 | 1.45M | 1.60M | 0.00 | 1.65M | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 128.13K | 3.00K | 21.00K | 774.88K | 593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 382.00K | 8.00K | 26.00K | 5.00K | 0.00 | 0.00 | 1.45M | 9.79M | 0.00 | 3.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 172.10K | 129.65K | 143.72K | 244.26K | 322.32K | 56.94K | 142.96K | 192.65K | 341.00K | 878.00K | 949.00K | 1.32M | 2.88M | 2.50M | 10.84M | 1.67M | 5.57M | 9.43M | 7.60M | 7.47M | 7.27M | 1.54M | 1.16M | 969.37K | 709.21K | 324.95K | 139.76K | 145.94K |
| EBITDA | -2.89M | -7.65M | -8.53M | -7.91M | -10.24M | 9.84M | -23.81M | -28.79M | -34.54M | -36.52M | -24.41M | -27.00M | -32.19M | -22.52M | -12.77M | -58.22M | -62.38M | -15.39M | -15.73M | 23.04M | -2.49M | -11.80M | -16.41M | -15.10M | -9.66M | -5.20M | -2.17M | -3.94M |
| EBITDA Ratio | -396.60% | -135.59% | -162.09% | -216.57% | -1,734.77% | 33.41% | -2,784.83% | -3,684.19% | -6,338.17% | -331,972.73% | -429.59% | -55.58% | -64.01% | -81.31% | -20.19% | -151.31% | -65.11% | -37.17% | -6.36% | 11.88% | -1.94% | -18.35% | -59.68% | -269.40% | -227.32% | -186.05% | -48.44% | -192.86% |
| Operating Income | -18.34M | -15.25M | -8.67M | -6.06M | -9.54M | 9.84M | -23.07M | -29.48M | -34.88M | -37.40M | -27.48M | -27.00M | -32.19M | -25.23M | -23.96M | -62.38M | -34.75M | -24.11M | 14.41M | 14.28M | -11.01M | -13.06M | -11.15M | -8.45M | -6.98M | -4.03M | -1.05M | -1.97M |
| Operating Income Ratio | -400.36% | -270.44% | -164.85% | -166.05% | -1,793.98% | 36.61% | -2,499.89% | -3,235.57% | -6,400.73% | -339,954.55% | -444.96% | -80.21% | -89.30% | -91.07% | -37.89% | -162.13% | -82.61% | -58.24% | 5.83% | 7.36% | -8.58% | -20.32% | -40.56% | -150.71% | -164.25% | -144.19% | -23.44% | -96.43% |
| Total Other Income/Expenses | 1.48M | -26.64M | 194.00K | 1.34M | 3.31M | -203.00K | 2.80M | 4.52M | -15.34M | 20.32M | 236.00K | 6.59M | 6.23M | 2.01M | -766.00K | 3.74M | 756.00K | 2.28M | -8.45M | -6.43M | -3.29M | 1.51M | 1.83M | 7.62M | 3.39M | 1.49M | 1.26M | 2.12M |
| Income Before Tax | -16.86M | -22.73M | -8.48M | -4.72M | -6.23M | 9.64M | -20.28M | -24.96M | -50.23M | -17.08M | -27.24M | -20.41M | -25.96M | -23.22M | -24.72M | -58.64M | -34.00M | -21.83M | 5.97M | 7.85M | -14.30M | -11.55M | -9.32M | 662.10K | -2.72M | -2.53M | 69.88K | 145.94K |
| Income Before Tax Ratio | -367.99% | -402.96% | -161.16% | -129.33% | -1,171.05% | 35.86% | -2,196.64% | -2,739.74% | -9,216.15% | -155,236.36% | -441.13% | -60.63% | -72.01% | -83.81% | -39.10% | -152.40% | -80.82% | -52.74% | 2.41% | 4.05% | -11.14% | -17.97% | -33.91% | 11.81% | -63.98% | -90.70% | 1.56% | 7.14% |
| Income Tax Expense | 3.00 | 14.94M | -109.00K | 395.00K | -188.00K | 5.45M | -3.48M | -4.52M | -85.00K | 111.00K | -34.06M | -27.00M | 1.10M | 26.00K | 5.00K | 1.18M | -1.96M | -29.13M | 7.33M | 6.89M | 4.57M | 2.81M | -2.98M | -662.10K | 2.72M | 2.53M | -69.88K | 72.97K |
| Net Income | -16.86M | -37.67M | -8.37M | -5.12M | -6.04M | 4.19M | -16.80M | -24.96M | -50.14M | -16.56M | 6.82M | -20.41M | -27.07M | -23.22M | -24.72M | -59.82M | -32.30M | 33.39M | 10.57M | -4.79M | -21.71M | -16.38M | -2.18M | 662.10K | -2.72M | -2.53M | 69.88K | 72.97K |
| Net Income Ratio | -367.99% | -667.89% | -159.09% | -140.14% | -1,135.71% | 15.58% | -1,819.72% | -2,739.74% | -9,200.55% | -150,581.82% | 110.36% | -60.63% | -75.08% | -83.81% | -39.10% | -155.46% | -76.77% | 80.67% | 4.27% | -2.47% | -16.91% | -25.48% | -7.92% | 11.81% | -63.98% | -90.70% | 1.56% | 3.57% |
| EPS | -3.47 | -7.76 | -1.82 | -3.11 | -8.63 | 6.37 | -28.07 | -60.29 | -453.60 | -701.63 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.60K | 3.45K | -1.58K | -7.57K | -6.37K | -1.06K | -3.30K | -1.59K | -1.56K | 0.00 | 0.00 |
| EPS Diluted | -3.47 | -7.76 | -1.82 | -3.11 | -8.63 | 6.14 | -28.07 | -58.51 | -366.08 | -701.60 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.30K | 3.45K | -1.56K | -7.57K | -6.37K | -1.03K | -3.30K | -1.59K | -1.36K | 0.00 | 0.00 |
| Weighted Avg Shares Out | 4.86M | 4.86M | 4.60M | 1.64M | 699.78K | 657.63K | 598.35K | 413.96K | 110.54K | 23.61K | 11.79K | 7.91K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.47K | 3.08K | 3.04K | 2.87K | 2.57K | 2.06K | 1.97K | 1.71K | 1.63K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 4.86M | 4.86M | 4.60M | 1.64M | 699.78K | 681.39K | 598.35K | 426.61K | 136.97K | 23.61K | 11.79K | 7.92K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.50K | 3.08K | 3.07K | 2.87K | 2.57K | 2.11K | 1.97K | 1.71K | 1.86K | 0.00 | 0.00 |
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini...
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors
3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared...
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28,...
Best Penny Stocks To Buy Now? 7 To Watch This Week
What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the U.S. District Court...
Source: https://incomestatements.info
Category: Stock Reports